Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10500123 | 0.84 | KAT2A (0.41) | DDAH1NPC1RAB9ASMN1; SMN2PSMB8 | |
| SCHEMBL16071123 | 0.81 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL16071120 | 0.81 | DYRK1A (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9813146 | 0.81 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL16061812 | 0.78 | NPC1 (0.40) | DDAH1NPC1RAB9ASMN1; SMN2PSMB8 | |
| SCHEMBL16071169 | 0.77 | APP (0.45) | SMN1; SMN2ALDH1A1TDP1HPGDALOX15 | |
| SCHEMBL16071168 | 0.77 | APP (0.39) | NPC1RAB9ASMN1; SMN2PSMB5ALDH1A1 | |
| SCHEMBL10592292 | 0.77 | MAPT (0.40) | DDAH1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16071170 | 0.76 | EPHX2 (0.50) | DYRK1AKDM4E | |
| SCHEMBL16071126 | 0.76 | DYRK1A (0.48) | DYRK1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868711-B2 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868711-B2 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160039776-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20140275045-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275045-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PCK2, MGST3, TXNRD2 | DDAH1 3965/4885NPC1 901/4885RAB9A 3377/4885 |
| US-20160039776-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PCK2, MGST3, TXNRD2 | DDAH1 3965/4885NPC1 901/4885RAB9A 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.